Giapreza is now available in the UK. 2.5mg/ml concentrate for solution for infusion vial, 1 x 1ml=£851.00 
Company plans on continuing commercial launch of product in Europe including the UK for 2022. Launch expected by the end of 2022/early 2023 in selected European countries 
Launched in Germany. PAION decided to make Giapreza available before establishing a commercial structure in Germany. Other European markets are to follow over the course of the next months in a staggered manner by country so that, by the end of 2022, launches will have been conducted in all selected European markets .
La Jolla has out-licensed Giapreza in Europe to PAION AG. Launch is expected in Europe in late 2021 .
La Jolla has agreed to supply Giapreza to an individual UK hospital using the UK Specials procedure in light of the COVID-19 pandemic. Other trusts wishing to obtain supplies are advised to contact La Jolla .
La Jolla expects to launch in Europe in early 2020 .
Approved in EU .
Recommended for EU approval by CHMP - the full indication is "for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies (see section 5.1)”. It is proposed that the drug be prescribed by physicians experienced in the treatment of shock and used in an acute and hospital setting .
According to the company, the EMA has accepted and validated the Marketing Authorisation Application for angiotensin II infusion. The indication being sought is treatment of hypotension in adults with distributive or vasodilatory shock who remain hypotensive despite fluid and vasopressor therapy, and the MAA is based on the results of the ATHOS-3 study (NCT02338843) .
Launched in US .
Approved in the US. Launch planned for March 2018. Analysts suggest use initially will be as a third-line treatment after noradrenaline and vasopressin have failed, but may also get some second-line use .
The FDA has accepted the New Drug Application for angiotensin II (LJPC-510) in the treatment of hypotension in adults with distributive or vasodilatory shock who remain hypotensive despite fluid and vasopressor therapy, according to a company statement. The application has been given Priority Review status, with a target action date of 28th Feb 2018 .
ATHOS-3 study (NCT02338843) is a PIII multi-national study recruiting in the US, EU (including UK) and elsewhere .